CAS: 94344-54-4; (E)-3-(3,4-Dihydroxyphenyl)-1-(4-Hydroxy-2-Methoxyphenyl)Prop-2-En-1-One
该化合物是一种生物活性食肉动物化合物,产自卡萨尔皮亚沙潘(Sappanwood)的心木,具有显著的抗氧化剂,抗炎和抗微生物特性,在制药和营养素研究中具有价值.在结构上,它属于铬亚类,以α为特征,不饱和的氯酮为特征,有助于其反应性氧物种的清除活动.研究显示,在减轻氧化性压力,抑制亲食性囊肿细胞和抑制细菌生长方面可能应用.其适度的生物利用率和稳定性进一步支持其在针对慢性炎和微生物感染的配方中的调查用途. SAppanchone通常通过溶剂提取和通过染色技术提纯化,确保研究应用的高纯度.
- 英文名称(E)-3-(3,4-Dihydroxyphenyl)-1-(4-Hydroxy-2-Methoxyphenyl)Prop-2-En-1-One
- 中文名称苏木查耳酮
- IUPAC名称(E)-3-(3,4-dihydroxyphenyl)-1-(4-hydroxy-2-methoxyphenyl)prop-2-en-1-one
- 其它别名Sappanchalcone; (2E)-3-(3,4-Dihydroxyphenyl)-1-(4-Hydroxy-2-Methoxyphenyl)-2-Propen-1-One; 3-(3,4-Dihydroxyphenyl)-1-(4-Hydroxy-2-Methoxyphenyl)Prop-2-En-1-One; Nonchalance; (E)-3-(3,4-Dihydroxyphenyl)-1-(4-Hydroxy-2-Methoxyphenyl)Prop-2-En-1-One; 2-Propen-1-One, 3-(3,4-Dihydroxyphenyl)-1-(4-Hydroxy-2-Methoxyphenyl)-, (2E)-
- CAS编号94344-54-4
- MFCD编号:MFCD20274974
- 分子式:C16H14O5分子量:286.28
- 产品CID: 1993558
- 产品分类天然产物 → 查尔酮类化合物
物理性质
MSDS等安全信息
上下游产品
1-(4-hydroxy-2-methoxy-phenyl)ethanone 3,4-dihydroxybenzaldehyde合成工艺路线路线简述
- 139-85-5 + 493-33-4 = 94344-54-4
反应条件:1.1 Reagents: Potassium Hydroxide Solvents: Ethanol; 6 H,Rt
标题:Preparation Of Phenylpropenone Compound For Treatment Of Lymphedema
参考文献:Korea]
155048-06-9 = 94344-54-4 + 34000-39-0 + 487-52-5 + 104236-79-5 + 10493-09-1 + 57601-14-6 + 21913-99-5
反应条件:1.1 Reagents: Sodium Ethanethiolate Solvents: Dimethylformamide; 4 H,Reflux1.2 Reagents: Hydrochloric Acid,Sodium Chloride Solvents: Water
标题:The Heck Coupling Reaction Using Aryl Vinyl Ketones: Synthesis Of Flavonoids
作者:Bianco,Armandodoriano; Cavarischia,Claudia; Guiso,Marcella
参考文献:European Journal Of Organic Chemistry 日期:2004 卷标:(13) 页码:2894-2898
📜1-(4-羟基-2-甲氧基苯基)乙酮,3,4-二羟基苯甲醛置于copper(Ll) Bromide体系中,用 乙酸乙酯 作为反应溶剂,以46%的收率获得产物苏木查耳酮
参考文献:Butein衍生物的合成和评估,用于抑制淋巴水肿的体内和体外炎症反应.
标题:Butein衍生物的合成和评估,用于抑制淋巴水肿的体内和体外炎症反应.
摘要:在本文中,我们证明,Butein(1)可以通过抑制肿瘤坏死因子α(tnf-α)的产生来预防小鼠淋巴水肿模型中的肿胀.合成并评估了butein衍生物,以鉴定具有体外抗炎活性的化合物.其中,20μm化合物7J,7M和14A在脂多糖刺激后表现出50%的抑制小鼠腹膜巨噬细胞tnf-α产生的作用.在鼠淋巴水肿模型中,化合物14A表现出最强的效力,体外ic50为14.6μm,肢体体积抑制了70%.在药代动力学研究中,通过口服给药,前药策略使化合物1的动力学溶解度增加了6倍,血液中的活性代谢产物水平提高了5倍,从而使化合物14A处于血液中.
DOI:10.1016/j.Ejmech.2020.112280
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2902500000-苯乙烯
2902600000-乙苯 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2010160351-A1
优先权日:2008-12-19
标题:Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
发明人：JENKINS HELEN; KITT MICHAEL; PEARLMAN RODNEY; SERAFINI TITO; THORSETT EUGENE
权利人:NUON THERAPEUTICS INC
摘要:Disclosed is a pharmaceutical composition comprising (a) a first therapeutic agent, wherein the first therapeutic agent is a compound of formula II: n n n n n n n n n n n n or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , X and n are as defined herein; (b) a second therapeutic agent, wherein the second therapeutic agent is a uric acid synthesis inhibitor or a uricosuric agent; and (c) a pharmaceutically acceptable diluent or carrier.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Jung EG, Han KI, Kwon HJ, Patnaik BB, Kim WJ, Hur GM, Nam KW, Han MD. Anti-inflammatory activity of sappanchalcone isolated from Caesalpinia sappan L. in a collagen-induced arthritis mouse model. Arch Pharm Res. 2015 Jun;38(6):973-83. doi: 10.1007/s12272-015-0557-z. Epub 2015 Jan 14. doi: 10.1016/j.ejphar.2010.06.059. Epub 2010 Jul 13. doi: 10.1016/j.tiv.2011.09.009. Epub 2011 Sep 19. doi: 10.1002/ptr.5321. Epub 2015 Mar 11. doi: 10.1016/S1875-5364(14)60092-3. doi: 10.1002/ptr.5307. Epub 2015 Feb 11. eCollection 2016.
8: Sasaki Y, Suzuki M, Matsumoto T, Hosokawa T, Kobayashi T, Kamata K, Nagumo S. Vasorelaxant activity of Sappan Lignum constituents and extracts on rat aorta and mesenteric artery. Biol Pharm Bull. 2010;33(9):1555-60. Japanese. doi: 10.1002/ptr.2982. doi: 10.3109/14756360903373376. Retraction in: J Enzyme Inhib Med Chem. 2012 Oct;27(5):758. doi: 10.1002/ptr.2670. doi: 10.1055/s-0028-1112208. Epub 2009 Jan 15. doi: 10.1055/s-0032-1327897. Epub 2012 Nov 15. doi: 10.1016/j.jep.2014.06.049. Epub 2014 Jun 26. Review.
合成参考文献
参考文献:10.1016/0031-9422(92)83658-l
摘要:Ogawa K, Aoki I, Sashida Y. Caesaljapin, a cassane diterpenoid from Caesalpinia decapetala var. Japonica. Phytochemistry. 1992 Aug;31(8):2897–8. doi: 10.1016/0031-9422(92)83658-l.
参考文献:10.1248/cpb.35.3568
摘要:NAMIKOSHI M, NAKATA H, NUNO M, OZAWA T, SAITOH T. Homoisoflavonoids and related compounds. III. Phenolic constituents of Caesalpinia japonica Sieb. et Zucc. Chem. Pharm. Bull. 1987;35(9):3568–75. doi: 10.1248/cpb.35.3568.
参考文献:10.1016/s1875-5364(14)60092-3
摘要:ZHANG Q, LIU J, QI X, QI C, YU Q. Inhibitory activities of Lignum Sappan extractives on growth and growth-related signaling of tumor cells. Chinese Journal of Natural Medicines. 2014 Aug;12(8):607–12. doi: 10.1016/s1875-5364(14)60092-3.
参考文献:10.1248/yakushi1947.104.9_935
摘要:Nagai M, Nagumo S, Eguchi I, Lee SM, Suzuki T. [Sappanchalcone from Caesalpinia sappan L., the proposed biosynthetic precursor of brazilin]. Yakugaku Zasshi. 1984 Sep;104(9):935–8. doi: 10.1248/yakushi1947.104.9_935.
参考文献:10.1007/s12272-015-0557-z
摘要:Jung EG, Han KI, Kwon HJ, Patnaik BB, Kim WJ, Hur GM, Nam KW, Han MD. Anti-inflammatory activity of sappanchalcone isolated from Caesalpinia sappan L. in a collagen-induced arthritis mouse model. Arch Pharm Res. 2015 Jun;38(6):973–83. doi: 10.1007/s12272-015-0557-z.
📝 需求与反馈
尽可能描述清楚需求与问题信息
